Title

CY-TB skin test: Detect and defeat

Authors

Aditi Bharti¹ & Tej Pratap Singh²

Affiliation

¹Department of Community and Family Medicine, AIIMS Bhopal, Madhya Pradesh, India; ²Department of Community Medicine, Sukh Sagar Medical College and Hospital, Jabalpur, Madhya Pradesh, India; *Corresponding author

Email

Aditi Bharti - E-mail: draditi2019@gmail.com; Phone: +91 9713196017
Tej Pratap Singh - E-mail: drtej2009@gmail.com; Phone: +91 9685496797

Article Type

Review

Date

Received July 1, 2025; Revised July 31, 2025; Accepted July 31, 2025, Published July 31, 2025

Abstract

Latent Tuberculosis Infection (LTBI) is a sustained immune response to Mycobacterium tuberculosis without clinical evidence of active disease, representing a substantial reservoir, contributes to the global burden of tuberculosis (TB). To address these gaps, Cy-Tb test (formerly C-Tb), developed by the Serum Institute of India, Pune, has been introduced under NTEP policy, combines the operational simplicity of TST with the specificity of IGRAs, expanded the coverage of high-risk groups and household contacts of pulmonary TB patients. Cy-Tb represents a next-generation LTBI diagnostic solution that supports early detection, operational alignment with point-of-care testing, cost-effectiveness, integration potential into national programs and contributes significantly towards the goal of TB elimination in India by 2025 and globally by 2035.

Keywords

Latent Tuberculosis Infection (LTBI), Cy-Tb, Tuberculin Skin Test (TST), Interferon γ Release Assay (IGRA), Tuberculosis Preventive Treatment (TPT).

Citation

Bharti & Singh, Bioinformation 21(7): 2218-2220 (2025)

Edited by

P Kangueane

ISSN

0973-2063

Publisher

Biomedical Informatics

License

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.